Papers by Charles M. Perou
Page 1 · newest first
- Transcriptomic Profiling of Mouse Mammary Tumors Enables Prognostic and Predictive Biomarker Discovery for Human Breast CancerCancer Research · 2026
- Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance)Journal of Clinical Investigation · 2026
- Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast CancerMolecular Cancer Therapeutics · 2026
- Abstract 2009: Targeting metabolic vulnerabilities in basal-like breast cancer.Cancer Research · 2026
- Abstract 375: BRD8 chromatin regulator mediates anti-HER2 response in HR+/HER2+ breast cancer.Cancer Research · 2026
- Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast CancerCancer Research · 2026
- Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancersNature Communications · 2026
- Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer2025
- HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapyNature Communications · 2025
- Prognostic significance of CD8+ T cell Spatial Biomarkers in ER+ and ER− breast cancer: A retrospective cohort studyPLoS Medicine · 2025
- Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal AdenocarcinomaJCO Precision Oncology · 2025
- Integration of Digital Histology and Gene Expression to Predict Treatment-Specific Responses in Breast Cancer2025
- Integrative proteogenomics and forward genetics reveals a novel mitotic vulnerability in triple-negative breast cancer.2025
- Overexpression of TSG101 causes the development of adenosquamous mammary carcinomaBreast Cancer Research · 2025
- Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast CancerJAMA Network Open · 2025
- Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL TrialJCO Precision Oncology · 2025
- Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersCell Reports Medicine · 2025
- Prognostic Significance of CD8 T-cell Spatial Biomarkers in ER+ and ER-Breast Cancer2025
- Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers2025
- B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancerJournal for ImmunoTherapy of Cancer · 2025
- 191MO Combination of talimogene laherparepvec (T-VEC) with atezolizumab (atezo) in patients (pts) with residual breast cancer (BC) after standard neoadjuvant chemotherapy (NAC): Survival results of the SOLTI-PROMETEO studyESMO Open · 2025
- HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabnpj Breast Cancer · 2025
- Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasetsnpj Breast Cancer · 2025
- Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancerJournal for ImmunoTherapy of Cancer · 2025
- Genomic Characteristics Related to Histology-Based Immune Features in Breast CancerModern Pathology · 2025
- Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profilingCell Genomics · 2025
- Understanding metastasis mixed-treatment responses through genomic analysesnpj Breast Cancer · 2025
- Genomic Analysis Reveals Racial and Age-Related Differences in the Somatic Landscape of Breast Cancer and the Association with Socioeconomic FactorsCancer Research · 2025
- Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapyCommunications Medicine · 2025
- Crafted experiments to evaluate feature selection methods for single-cell RNA-seq dataNAR Genomics and Bioinformatics · 2025
- Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer2024
- Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)Annals of Oncology · 2024
- Generative adversarial networks accurately reconstruct pan-cancer histology from pathologic, genomic, and radiographic latent featuresScience Advances · 2024
- TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapyAnnals of Oncology · 2024
- Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinome2024
- Single‐cell transcriptional atlas of human breast cancers and model systemsClinical and Translational Medicine · 2024
- Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growthScience Advances · 2024
- Supplementary Data1 from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial2024
- Supplementary Data1 from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial2024
- Data from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial2024
- Supplementary Figure S2 from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
- Supplementary Figure S1 from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
- Supplementary Figure S1 from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
- Data from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
- Supplementary Figure S2 from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
- Stain SAN: simultaneous augmentation and normalization for histopathology imagesJournal of Medical Imaging · 2024
- Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502npj Breast Cancer · 2024
- Development and Characterization of Syngeneic Orthotopic Transplant Models of Obesity-Responsive Triple-Negative Breast Cancer in C57BL/6J MiceCancers · 2024
- Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapyBiomaterials · 2024
- Associations of immune checkpoint predictive biomarkers MHC-I and MHC-II with clinical and molecular features in a diverse breast cancer cohortClinical Cancer Research · 2024